Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gilteritinib”

54 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 54 results

Early research (Phase 1)Study completedNCT03625505
What this trial is testing

Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia (AML)
AbbVie 61
Large-scale testing (Phase 3)Study completedNCT02421939
What this trial is testing

ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

Who this might be right for
Leukemia, Acute Myeloid (AML)
Astellas Pharma Global Development, Inc. 371
Testing effectiveness (Phase 2)Looking for participantsNCT06561880
What this trial is testing

The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation

Who this might be right for
FLT3 Gene MutationAML
Institute of Hematology & Blood Diseases Hospital, China 66
Testing effectiveness (Phase 2)Study completedNCT02561455
What this trial is testing

Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial

Who this might be right for
Advanced Solid TumorsAcute Myeloid Leukemia
Astellas Pharma Global Development, Inc. 9
Early research (Phase 1)Study completedNCT03964038
What this trial is testing

Assess the Relative Bioavailability of Gilteritinib Following a Single Dose of Gilteritinib Mini-tablet Oral Suspension and Gilteritinib Mini-tablets Compared to a Single Dose of Gilteritinib Tablet in Healthy Subjects

Who this might be right for
Healthy Volunteer
Astellas Pharma Global Development, Inc. 48
Early research (Phase 1)Ended earlyNCT04477291
What this trial is testing

CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Aptose Biosciences Inc. 45
Not applicableNo Longer AvailableNCT03315299
What this trial is testing

Individual Patient Expanded Access Gilteritinib (ASP2215)

Who this might be right for
AML
Etan Orgel
Testing effectiveness (Phase 2)Looking for participantsNCT06022003
What this trial is testing

Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia

Who this might be right for
AML, AdultRefractory AMLRelapsed Adult AML+2 more
French Innovative Leukemia Organisation 33
Early research (Phase 1)WithdrawnNCT05330377
What this trial is testing

GM-CLAG in Relapsed/Refractory FLT3-mutated AML

Who this might be right for
Acute Myeloid Leukemia
Ayman H Qasrawi
Testing effectiveness (Phase 2)Active Not RecruitingNCT05520567
What this trial is testing

Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia (AML)FLT3-mutated Acute Myeloid Leukemia
Astellas Pharma Global Development, Inc. 70
Not applicableUnknownNCT05791890
What this trial is testing

GilteRInf 2022 Study (Gilteritinib Related Infections)

Who this might be right for
Acute Myeloid Leukemia
University of Rome Tor Vergata 78
Large-scale testing (Phase 3)Not Yet RecruitingNCT07407140
What this trial is testing

VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML

Who this might be right for
AML, Adult
Institute of Hematology & Blood Diseases Hospital, China 300
Large-scale testing (Phase 3)Looking for participantsNCT04293562
What this trial is testing

Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Who this might be right for
Acute Myeloid Leukemia
Children's Oncology Group 1,186
Early research (Phase 1)Looking for participantsNCT05010772
What this trial is testing

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

Who this might be right for
Acute Myeloid Leukemia
M.D. Anderson Cancer Center 125
Testing effectiveness (Phase 2)Looking for participantsNCT07259707
What this trial is testing

Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML

Who this might be right for
Acute Myeloid LeukemiaFLT3 Internal Tandem Duplication PositiveIntermediate Risk Acute Myeloid Leukemia+1 more
First Affiliated Hospital of Zhejiang University 25
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06652685
What this trial is testing

Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia (AML)
Ruijin Hospital 218
Testing effectiveness (Phase 2)Looking for participantsNCT04140487
What this trial is testing

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Who this might be right for
Recurrent Acute Myeloid LeukemiaRecurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic/Myeloproliferative Neoplasm+3 more
M.D. Anderson Cancer Center
Large-scale testing (Phase 3)Study completedNCT02752035
What this trial is testing

ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

Who this might be right for
Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Astellas Pharma Global Development, Inc. 183
Testing effectiveness (Phase 2)Study completedNCT02927262
What this trial is testing

ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission

Who this might be right for
Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation
Astellas Pharma Global Development, Inc. 98
Early research (Phase 1)Looking for participantsNCT05546580
What this trial is testing

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

Who this might be right for
Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia Refractory
Oryzon Genomics S.A. 50
Load More Results
97